Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of symptomatic multiple myeloma as defined by International Myeloma Working Group (IMWGURC).~* Phase 1: Relapsed or relapsed/refractory myeloma after at least 1 previous treatments and with a life expectancy of more than 3 months.~* Phase 2: Measurable (as defined by IMWGURC) disease after at least 1 previous treatment.~Exclusion Criteria:~* History of allogeneic stem cell transplant.~* Phase 2 only: Prior bortezomib therapy will only be allowed if there was a demonstrated positive response, and disease progression occurred off therapy.~* Must have not experienced significant blood level changes, e.g. very low platelets, while on previous bortezomib therapy~* Prior radiation therapy to \> 25% of the bone marrow (whole pelvis is 25%).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).